Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06762964 · ClinicalTrials.gov registry record · Phase 2
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
A Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06762964 is a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 27 participants, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06762964, a Phase 2 study of HFpEF - Heart Failure With Preserved Ejection Fraction and Single Ventricle Heart Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
Conditions Studied
Interventions
- DRUG Dapagliflozin tablet
- DRUG Placebo Tablet
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06762964
The ClinicalTrials.gov registry entry for NCT06762964 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,876-participant average among 6 other HFpEF - Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (100% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HFpEF - Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin tablet is the first listed.
NCT06762964 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06762964 about?
NCT06762964 is a clinical study titled "CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation". The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
What is the current status of trial NCT06762964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-05-16. Estimated completion is 2027-02.
What conditions does trial NCT06762964 study?
This clinical trial studies the following conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, Single Ventricle Heart Disease, Fontan Circulation.
What interventions are being tested in trial NCT06762964?
The interventions under investigation include: Dapagliflozin tablet (DRUG), Placebo Tablet (DRUG).
Who is sponsoring clinical trial NCT06762964?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06762964 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HFpEF - Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailored Exercise Training Study Among Adults With HFpEF
RECRUITING · Phase 2
-
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
RECRUITING · Phase 2
-
MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
US Benchmarking Clinical Study
RECRUITING
-
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
COMPLETED
Explore more on PlainTrial
HFpEF - Heart Failure With Preserved Ejection Fraction
All registered trials for this condition
Single Ventricle Heart Disease
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.